Showing 1 - 12 results of 12 for search 'Chenglong Han', query time: 0.04s
Refine Results
-
1
-
2
-
3
Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalim... by Kristian Reich, Peter Foley, Chenglong Han, Sean McElligott, Erik Muser, Nan Li, April W. Armstrong
Published 2020-08-01
Article -
4
-
5
Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study by Laura K. Ferris, Elyssa Ott, Jingzhi Jiang, H. Chih-Ho Hong, Shu Li, Chenglong Han, Wojciech Baran
Published 2020-02-01
Article -
6
Development of a patient-reported outcome questionnaire for use in adults with moderate-to-severe plaque psoriasis: The Psoriasis Symptoms and Signs Diary by Steven R. Feldman, Susan D. Mathias, Brad Schenkel, Hilary H. Colwell, Kelly McQuarrie, Bruce Randazzo, Chenglong Han
Published 2016-01-01
Article -
7
Validation of psychometric properties and development of response criteria for the psoriasis symptoms and signs diary (PSSD): results from a phase 3 clinical trial by April Armstrong, Luis Puig, Richard Langley, Tsen Fang Tsai, Michael Song, Yasmine Wasfi, Jingzhi Jiang, Shu Li, Chenglong Han
Published 2019-01-01
Article -
8
Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1 by Christopher E. M. Griffiths, Kim A. Papp, Michael Song, Megan Miller, Yin You, Yaung-Kaung Shen, Chenglong Han, Andrew Blauvelt
Published 2022-02-01
Article -
9
Assessing the Attractive Effects of Floating Artificial Reefs and Combination Reefs on Six Local Marine Species by Chenglong Han, Kefeng Liu, Toshihisa Kinoshita, Biao Guo, Yifan Zhao, Yuhang Ye, Yufei Liu, Osamu Yamashita, Debin Zheng, Wenhui Wang, Xueqiang Lu
Published 2023-05-01
Article -
10
Qualitative and psychometric evaluation of the PROMIS®-Fatigue SF-7a scale to assess fatigue in patients with moderately to severely active inflammatory bowel disease by Brian G. Feagan, William J. Sandborn, Bruce E. Sands, Yan Liu, Marion Vetter, Susan D. Mathias, Kuan-Hsiang Gary Huang, Jewel Johanns, Matthew Germinaro, Chenglong Han
Published 2023-11-01
Article -
11
Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of 1120 patients with ac... by Proton Rahman, Philip J. Mease, Philip S. Helliwell, Atul Deodhar, Laure Gossec, Arthur Kavanaugh, Alexa P. Kollmeier, Elizabeth C. Hsia, Bei Zhou, Xiwu Lin, May Shawi, Chetan S. Karyekar, Chenglong Han
Published 2021-07-01
Article -
12
Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis by Jeffrey R. Curtis, Iain B. McInnes, Proton Rahman, Dafna D. Gladman, Steven Peterson, Feifei Yang, Oluwakayode Adejoro, Alexa P. Kollmeier, Natalie J. Shiff, Chenglong Han, May Shawi, William Tillett, Philip J. Mease
Published 2024-02-01
Article